CMP-001 in combination with pembrolizumab continues to demonstrate durable responses in anti-PD-1 refractory melanoma in ongoing trial Encouraging new data on pathological responses and 1-year RFS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback